Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GARY MICHAEL REISS

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1568666543
CMS profile
25373
Location
MARRERO, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,987.96

130 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,987.96 130

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GARY MICHAEL REISS

NPI 1568666543 · CMS profile ID 25373

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

MARRERO, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568666543?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GARY MICHAEL REISS, NPI 1568666543, CMS profile ID 25373. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568666543?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GARY MICHAEL REISS, NPI 1568666543, CMS profile ID 25373. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568666543?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GARY MICHAEL REISS, NPI 1568666543, CMS profile ID 25373, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1568666543?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

130 matching records · $1,987.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 130 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–130 of 130.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Phathom Pharmaceuticals, Inc. $7.4403/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219351970 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.4703/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223828806 CMS
ABBVIE INC. $11.5203/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203826026 CMS
ABBVIE INC. $7.4903/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203826013 CMS
ABBVIE INC. $0.5803/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203826019 CMS
Celltrion USA Inc. $14.6303/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250830604 CMS
Ardelyx, Inc. $27.4603/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247878445 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6.3803/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223802225 CMS
ABBVIE INC. $5.7602/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203826009 CMS
ABBVIE INC. $0.5202/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203826003 CMS
Lilly USA, LLC $15.1502/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186602244 CMS
PFIZER INC. $10.2202/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231576032 CMS
ABBVIE INC. $11.1602/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203825997 CMS
ABBVIE INC. $0.7702/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203825987 CMS
ABBVIE INC. $10.9302/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203825992 CMS
Phathom Pharmaceuticals, Inc. $11.3602/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219351894 CMS
ABBVIE INC. $25.8802/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203825982 CMS
Celltrion USA Inc. $5.4702/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250830602 CMS
GENZYME CORPORATION $24.0402/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233723136 CMS
ABBVIE INC. $7.0101/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203825970 CMS
ABBVIE INC. $0.5901/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203825976 CMS
Regeneron Healthcare Solutions, Inc. $17.1301/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213022963 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.1801/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223808174 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.5701/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231887615 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.4201/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223808474 CMS
ABBVIE INC. $14.1001/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203825958 CMS
ABBVIE INC. $9.1001/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203825963 CMS
Ipsen Biopharmaceuticals, Inc $26.0701/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208833656 CMS
Celltrion USA Inc. $17.4501/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250830600 CMS
Daiichi Sankyo Inc. $29.1201/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197076801 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,958.32 46
PY2020 $14,208.21 18
PY2021 $16,814.61 35
PY2022 $5,424.91 46
PY2023 $4,221.78 67
PY2024 $2,560.11 134
PY2025 $1,987.96 130

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $585,490.76 277
PY2024 Principal investigator $1,428,217.32 288
PY2023 Recipient $48.50 1
PY2023 Principal investigator $1,178,528.96 493
PY2022 Recipient $9,282.61 2
PY2022 Principal investigator $1,335,502.11 758
PY2021 Principal investigator $1,416,189.45 333
PY2020 Recipient $9,786.69 1
PY2020 Principal investigator $1,898,224.92 171
PY2019 Recipient $2,269.77 1
PY2019 Principal investigator $2,063,421.55 95

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

277 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $1,925.00 12/31/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716166
Principal investigator 1 Boehringer Ingelheim International GmbH $1,589.00 12/31/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716168
Principal investigator 1 Boehringer Ingelheim International GmbH $4,719.40 12/30/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716174
Principal investigator 1 Boehringer Ingelheim International GmbH $3,626.00 12/26/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716234
Principal investigator 1 Boehringer Ingelheim International GmbH $4,956.00 12/22/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716164
Principal investigator 1 Boehringer Ingelheim International GmbH $4,613.00 12/22/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716178
Principal investigator 1 Boehringer Ingelheim International GmbH $4,919.60 12/19/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716170
Principal investigator 1 Boehringer Ingelheim International GmbH $4,719.40 12/19/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716180
Principal investigator 1 Boehringer Ingelheim International GmbH $4,719.40 12/19/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716184
Principal investigator 1 Boehringer Ingelheim International GmbH $4,579.40 12/19/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716192
Principal investigator 1 Boehringer Ingelheim International GmbH $1,365.00 12/19/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716230
Principal investigator 1 Madrigal Pharmaceuticals $2,238.86 12/19/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254460
Principal investigator 1 Madrigal Pharmaceuticals $637.88 12/19/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 12/19/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279466
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279468
Principal investigator 1 Boehringer Ingelheim International GmbH $2,527.00 12/18/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716162
Principal investigator 1 Boehringer Ingelheim International GmbH $4,422.60 12/18/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716172
Principal investigator 1 Boehringer Ingelheim International GmbH $3.64 12/17/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716232
Principal investigator 1 Janssen Research & Development, LLC $236.00 12/17/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175223933
Principal investigator 1 Janssen Research & Development, LLC $1,058.00 12/17/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175223954
Principal investigator 1 Janssen Research & Development, LLC $1,058.00 12/17/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175223977
Principal investigator 1 Janssen Research & Development, LLC $236.00 12/17/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175224018
Principal investigator 1 Janssen Research & Development, LLC $1,497.00 12/17/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175224034
Principal investigator 1 Janssen Research & Development, LLC $236.00 12/17/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175224052
Principal investigator 1 Janssen Research & Development, LLC $1,497.00 12/17/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175224088
Principal investigator 1 Janssen Research & Development, LLC $236.00 12/17/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175224105
Principal investigator 1 Janssen Research & Development, LLC $236.00 12/17/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175224114
Principal investigator 1 Janssen Research & Development, LLC $236.00 12/17/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175224139
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/12/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716182
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 12/12/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716186
Principal investigator 1 Boehringer Ingelheim International GmbH $770.00 12/12/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716188
Principal investigator 1 Boehringer Ingelheim International GmbH $10,920.00 12/12/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716190
Principal investigator 1 Ipsen Bioscience Inc. $500.00 12/11/2025 Non-covered Recipient Entity
Tandem Clinical Research
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176547187
Principal investigator 1 Madrigal Pharmaceuticals $1,917.89 12/11/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253970
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,438.00 12/11/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050502
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,300.00 12/11/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050504
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/10/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716176
Principal investigator 1 Madrigal Pharmaceuticals $222.75 12/04/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248253474
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,799.30 12/04/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184269595
Principal investigator 1 Senseonics, Incorporated $87.75 12/04/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852999
Principal investigator 1 Senseonics, Incorporated $400.00 12/04/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249853001
Principal investigator 1 Madrigal Pharmaceuticals $2,238.86 11/25/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/20/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $299.70 11/20/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $372.73 11/20/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.30 11/20/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263387
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 11/19/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716236
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 11/19/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716238
Principal investigator 1 GlaxoSmithKline, LLC. $15,550.00 11/14/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192135127
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $300.81 11/14/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050500
Principal investigator 1 Madrigal Pharmaceuticals $100.00 11/07/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,336.65 11/07/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 11/07/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258081
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $485.00 11/07/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050496
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,063.00 11/07/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050498
Principal investigator 1 Janssen Research & Development, LLC $236.00 11/03/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175223919
Principal investigator 1 GlaxoSmithKline, LLC. $4,809.00 10/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192127777
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716194
Principal investigator 1 Senseonics, Incorporated $87.75 10/23/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852991
Principal investigator 1 Senseonics, Incorporated $2,267.81 10/23/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852993
Principal investigator 1 Senseonics, Incorporated $87.75 10/23/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852995
Principal investigator 1 Senseonics, Incorporated $87.75 10/23/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852997
Principal investigator 1 Boehringer Ingelheim International GmbH $1,213.84 10/17/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716228
Principal investigator 1 Madrigal Pharmaceuticals $222.75 10/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248251652
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,250.00 10/16/2025 Non-covered Recipient Entity
Tandem Clinical Research LLC
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211661205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 10/16/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,336.65 10/03/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244917
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,438.00 10/03/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050494
Principal investigator 1 Senseonics, Incorporated $87.75 10/02/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852983
Principal investigator 1 Senseonics, Incorporated $87.75 10/02/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852985
Principal investigator 1 Senseonics, Incorporated $2,267.81 10/02/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852987
Principal investigator 1 Senseonics, Incorporated $87.75 10/02/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852989
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 09/24/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716154
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 09/24/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716156
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 09/24/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716158
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 09/24/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716160
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 09/24/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716220
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 09/24/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716222
Principal investigator 1 Boehringer Ingelheim International GmbH $1,095.00 09/24/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716224
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 09/24/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716226
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $997.50 09/23/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184241830
Principal investigator 1 GlaxoSmithKline, LLC. $4,809.00 09/16/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192138491
Principal investigator 1 Madrigal Pharmaceuticals $1,917.89 09/12/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,796.65 09/12/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236830
Principal investigator 1 Madrigal Pharmaceuticals $10,928.25 08/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248249279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,290.00 08/26/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184230531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 08/26/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184230533
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $100.00 08/26/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050492
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 08/22/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192127760
Principal investigator 1 Madrigal Pharmaceuticals $2,314.91 08/22/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248996
Principal investigator 1 Senseonics, Incorporated $87.75 08/21/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852977
Principal investigator 1 Senseonics, Incorporated $2,267.81 08/21/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852979
Principal investigator 1 Senseonics, Incorporated $87.75 08/21/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852981
Principal investigator 1 Madrigal Pharmaceuticals $1,235.25 08/18/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248724
Principal investigator 1 Madrigal Pharmaceuticals $1,235.25 08/18/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248727
Principal investigator 1 Madrigal Pharmaceuticals $1,755.00 08/18/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248731
Principal investigator 1 GlaxoSmithKline, LLC. $3,739.77 08/12/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123545
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 08/01/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192127732
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 08/01/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192129734
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 08/01/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192135096
Principal investigator 1 Madrigal Pharmaceuticals $15,990.21 07/31/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247772
Principal investigator 1 Madrigal Pharmaceuticals $1,873.13 07/31/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247881
Principal investigator 1 Senseonics, Incorporated $87.75 07/31/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852973
Principal investigator 1 Senseonics, Incorporated $87.75 07/31/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852975
Principal investigator 1 Madrigal Pharmaceuticals $222.75 07/30/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248247634
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 07/28/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716152
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 07/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192135089
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 07/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192135111
Principal investigator 1 Madrigal Pharmaceuticals $1,235.25 07/22/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,435.80 07/22/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 07/22/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217983
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 07/22/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050486
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 07/22/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050488
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,000.00 07/22/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244050490
Principal investigator 1 Madrigal Pharmaceuticals $87.19 07/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247138
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,489.65 07/16/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis No dispute reported 06/30/2026 1185551808
Principal investigator 1 Boehringer Ingelheim International GmbH $8,050.00 07/16/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716150
Principal investigator 1 GlaxoSmithKline, LLC. $4,809.00 07/16/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192127753
Principal investigator 1 Bausch Health US, LLC $1,722.40 07/14/2025 Non-covered Recipient Entity
Tandem Clinical Research GI, LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224846245
Principal investigator 1 GlaxoSmithKline, LLC. $1,755.74 07/14/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192127738
Principal investigator 1 Madrigal Pharmaceuticals $7,215.75 07/09/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246706
Principal investigator 1 Boehringer Ingelheim International GmbH $10,800.00 06/30/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716142
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 06/26/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192138496
Principal investigator 1 Senseonics, Incorporated $2,267.81 06/26/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852967
Principal investigator 1 Senseonics, Incorporated $2,267.81 06/26/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852969
Principal investigator 1 Senseonics, Incorporated $2,267.81 06/26/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852971
Principal investigator 1 GlaxoSmithKline, LLC. $1,025.13 06/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192129747
Principal investigator 1 GlaxoSmithKline, LLC. $993.01 06/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192135103
Principal investigator 1 Madrigal Pharmaceuticals $1,235.25 06/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246065
Principal investigator 1 Madrigal Pharmaceuticals $2,238.86 06/19/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245815
Principal investigator 1 Madrigal Pharmaceuticals $222.75 06/19/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248245823
Principal investigator 1 Madrigal Pharmaceuticals $1,235.25 06/18/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245733
Principal investigator 1 Madrigal Pharmaceuticals $2,403.00 06/16/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245659
Principal investigator 1 GlaxoSmithKline, LLC. $4,545.18 06/12/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 06/12/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184206651
Principal investigator 1 Bausch Health US, LLC $7,025.53 06/11/2025 Non-covered Recipient Entity
Tandem Clinical Research GI, LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224846252
Principal investigator 1 Janssen Research & Development, LLC $315.00 06/11/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175224131
Principal investigator 1 Madrigal Pharmaceuticals $1,255.57 06/05/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248244957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,184.75 06/05/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184204451
Principal investigator 1 Senseonics, Incorporated $87.75 05/29/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852955
Principal investigator 1 Senseonics, Incorporated $87.75 05/29/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852957
Principal investigator 1 Senseonics, Incorporated $87.75 05/29/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852959
Principal investigator 1 Senseonics, Incorporated $2,267.81 05/29/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852961
Principal investigator 1 Senseonics, Incorporated $87.75 05/29/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852963
Principal investigator 1 Senseonics, Incorporated $87.75 05/29/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852965
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 05/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192129710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.50 05/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184199091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184199095
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 05/27/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716144
Principal investigator 1 Boehringer Ingelheim International GmbH $912.50 05/27/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716146
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 05/27/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716148
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 05/27/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716216
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 05/27/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716218
Principal investigator 1 GlaxoSmithKline, LLC. $5,267.23 05/26/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192123549
Principal investigator 1 Madrigal Pharmaceuticals $1,527.46 05/23/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244429
Principal investigator 1 Madrigal Pharmaceuticals $2,238.86 05/22/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244232
Principal investigator 1 Madrigal Pharmaceuticals $8,504.26 05/15/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243736
Principal investigator 1 Madrigal Pharmaceuticals $1,235.25 05/15/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,369.50 05/15/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184194981
Principal investigator 1 PFIZER INC. $2,500.00 05/10/2025 Non-covered Recipient Entity
Tandem Clinical Research GI LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER CACHEXIA AND ELEVATED CONCENTRATIONS OF GDF15 FOLLOWED BY AN OPTIONAL OPENLABEL TREATMENT PERIOD No dispute reported 06/30/2026 1228772454
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $86.80 05/09/2025 Non-covered Recipient Individual A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244045516
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.44 05/09/2025 Non-covered Recipient Individual A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244045518
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9.11 05/09/2025 Non-covered Recipient Individual A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244045520
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $42.70 05/09/2025 Non-covered Recipient Individual A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244045522
Principal investigator 1 Madrigal Pharmaceuticals $1,437.75 04/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,435.80 04/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184190629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $208.00 04/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184190631
Principal investigator 1 Madrigal Pharmaceuticals $1,238.89 04/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248242609
Principal investigator 1 Senseonics, Incorporated $2,267.81 04/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852945
Principal investigator 1 Senseonics, Incorporated $2,267.81 04/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852947
Principal investigator 1 Senseonics, Incorporated $2,267.81 04/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852949
Principal investigator 1 Senseonics, Incorporated $87.75 04/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852951
Principal investigator 1 Senseonics, Incorporated $87.75 04/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852953
Principal investigator 1 Madrigal Pharmaceuticals $4,515.75 04/23/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242555
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 04/17/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716206
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 04/17/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716208
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 04/17/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716210
Principal investigator 1 Boehringer Ingelheim International GmbH $11,000.00 04/17/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716212
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 04/17/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716214
Principal investigator 1 GlaxoSmithKline, LLC. $4,316.90 04/10/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192129728
Principal investigator 1 Madrigal Pharmaceuticals $1,917.89 04/08/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,184.75 04/08/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184181918
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 04/04/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192129740
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 04/04/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192129753
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 04/04/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192135122
Principal investigator 1 Senseonics, Incorporated $87.75 04/03/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852929
Principal investigator 1 Senseonics, Incorporated $87.75 04/03/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852931
Principal investigator 1 Senseonics, Incorporated $87.75 04/03/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852933
Principal investigator 1 Senseonics, Incorporated $87.75 04/03/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852935
Principal investigator 1 Senseonics, Incorporated $87.75 04/03/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852937
Principal investigator 1 Senseonics, Incorporated $87.75 04/03/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852939
Principal investigator 1 Senseonics, Incorporated $87.75 04/03/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852941
Principal investigator 1 Senseonics, Incorporated $87.75 04/03/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852943
Principal investigator 1 Janssen Research & Development, LLC $445.00 04/01/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175223879
Principal investigator 1 Janssen Research & Development, LLC $8,500.00 04/01/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175223985
Principal investigator 1 Janssen Research & Development, LLC $248.00 04/01/2025 Non-covered Recipient Entity
Tandem Intermediate Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175224010
Principal investigator 1 Madrigal Pharmaceuticals $100.00 04/01/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241486
Principal investigator 1 Senseonics, Incorporated $2,267.81 03/27/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852921
Principal investigator 1 Senseonics, Incorporated $2,317.81 03/27/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852923
Principal investigator 1 Senseonics, Incorporated $87.75 03/27/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852925
Principal investigator 1 Senseonics, Incorporated $2,317.81 03/27/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852927
Principal investigator 1 Boehringer Ingelheim International GmbH $279.84 03/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716134
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 03/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716136
Principal investigator 1 Boehringer Ingelheim International GmbH $1,058.50 03/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716138
Principal investigator 1 Boehringer Ingelheim International GmbH $16.00 03/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716140
Principal investigator 1 GlaxoSmithKline, LLC. $9,844.47 03/21/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192129716
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 03/20/2025 Non-covered Recipient Entity
Tandem Clinic Rsrch Gi Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175223886
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 03/19/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223276775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 03/19/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223276777
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 03/19/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223276779
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 03/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192127773
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 03/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192138483
Principal investigator 1 Madrigal Pharmaceuticals $20,332.60 03/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241032
Principal investigator 1 Senseonics, Incorporated $87.75 03/13/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852917
Principal investigator 1 Bausch Health US, LLC $965.08 03/11/2025 Non-covered Recipient Entity
Tandem Clinical Research GI, LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224846249
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 03/06/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716114
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 03/06/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716116
Principal investigator 1 Boehringer Ingelheim International GmbH $11,000.00 03/06/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716118
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 03/06/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716120
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 03/06/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716122
Principal investigator 1 Madrigal Pharmaceuticals $3,567.20 03/06/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240580
Principal investigator 1 Senseonics, Incorporated $2,317.81 03/06/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852919
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 02/28/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716098
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 02/28/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716100
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 02/28/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716102
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 02/28/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716104
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/28/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716106
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/28/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716108
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 02/28/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716110
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 02/28/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716112
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 02/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716124
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716126
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 02/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716128
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 02/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716130
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 02/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220716132
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 02/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716196
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716198
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 02/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716200
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 02/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716202
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 02/25/2025 Non-covered Recipient Entity
Tandem Clinical Research-Marrero Clinic
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220716204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,435.80 02/25/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184155564
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 02/25/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184155566
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,057.30 02/25/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223275517
Principal investigator 1 GlaxoSmithKline, LLC. $4,769.62 02/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192127767
Principal investigator 1 GlaxoSmithKline, LLC. $3,467.00 02/24/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192135115
Principal investigator 1 Janssen Research & Development, LLC $477.00 02/19/2025 Non-covered Recipient Entity
Tandem Clinic Rsrch Gi Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175223948
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 02/18/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,290.00 02/18/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154648
Principal investigator 1 Senseonics, Incorporated $2,317.81 02/13/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852915
Principal investigator 1 Madrigal Pharmaceuticals $2,392.07 02/06/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239395
Principal investigator 1 Madrigal Pharmaceuticals $27,918.01 02/06/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239399
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $212.00 01/29/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223274523
Principal investigator 1 GlaxoSmithKline, LLC. $1,274.00 01/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192127746
Principal investigator 1 GlaxoSmithKline, LLC. $3,555.00 01/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1192129722
Principal investigator 1 GlaxoSmithKline, LLC. $11,273.17 01/28/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192135084
Principal investigator 1 Janssen Research & Development, LLC $236.00 01/27/2025 Non-covered Recipient Entity
Tandem Clinic Rsrch Gi Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175224099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,435.80 01/21/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,483.00 01/21/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,250.00 01/21/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,900.00 01/21/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,732.00 01/21/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184149192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,435.80 01/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,290.00 01/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 01/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $537.50 01/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 01/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 01/17/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148301
Principal investigator 1 Senseonics, Incorporated $2,317.81 01/16/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852909
Principal investigator 1 Senseonics, Incorporated $2,317.81 01/16/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852911
Principal investigator 1 Senseonics, Incorporated $2,317.81 01/16/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI, LLC
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852913
Principal investigator 1 Madrigal Pharmaceuticals $1,873.13 01/09/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,660.64 01/09/2025 Non-covered Recipient Entity
TANDEM INTERMEDIATE LLC
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD No dispute reported 06/30/2026 1184147373
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 01/09/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223273833
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,500.00 01/09/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223273835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,000.00 01/09/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223273837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,723.90 01/07/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 No dispute reported 06/30/2026 1223273615
Principal investigator 1 Madrigal Pharmaceuticals $1,238.89 01/06/2025 Non-covered Recipient Entity
TANDEM CLINICAL RESEARCH GI LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238056

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $8,195.02 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $8,195.02 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $519.09 1
PY2021 Amount invested $435.44 1
PY2021 Value of interest $544.45 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2021–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 GastroGPO, LLC $0.00 $8,195.02 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124820124
PY2023 GastroGPO, LLC $0.00 $8,195.02 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1050730553
PY2022 GastroGPO, LLC $0.00 $519.09 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 955001039
PY2021 GastroGPO, LLC $435.44 $544.45 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 854914441